Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N.

J Clin Invest. 2016 Aug 1;126(8):3036-52. doi: 10.1172/JCI83416. Epub 2016 Jul 18.

PMID:
27427982
2.

Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment.

Nguyen HH, Kim T, Song SY, Park S, Cho HH, Jung SH, Ahn JS, Kim HJ, Lee JJ, Kim HO, Cho JH, Yang DH.

Sci Rep. 2016 Jun 16;6:28208. doi: 10.1038/srep28208.

3.

CAR T Cell Therapy: A Game Changer in Cancer Treatment.

Almåsbak H, Aarvak T, Vemuri MC.

J Immunol Res. 2016;2016:5474602. doi: 10.1155/2016/5474602. Epub 2016 May 19. Review.

4.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.

PMID:
27270177
5.

Clinical development of gene therapy: results and lessons from recent successes.

Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW.

Mol Ther Methods Clin Dev. 2016 May 25;3:16034. doi: 10.1038/mtm.2016.34. eCollection 2016. Review.

6.

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Park JH, Geyer MB, Brentjens RJ.

Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20. Review.

PMID:
27207800
7.

Toxicities of chimeric antigen receptor T cells: recognition and management.

Brudno JN, Kochenderfer JN.

Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20. Review.

PMID:
27207799
8.

New Strategies for the Treatment of Solid Tumors with CAR-T Cells.

Zhang H, Ye ZL, Yuan ZG, Luo ZQ, Jin HJ, Qian QJ.

Int J Biol Sci. 2016 Apr 28;12(6):718-29. doi: 10.7150/ijbs.14405. eCollection 2016. Review.

9.

Targeted immunotherapy for pediatric solid tumors.

Kopp LM, Katsanis E.

Oncoimmunology. 2015 Aug 31;5(3):e1087637. eCollection 2016 Mar. Review.

PMID:
27141344
10.

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers.

Thomas S, Straathof K, Himoudi N, Anderson J, Pule M.

PLoS One. 2016 Mar 31;11(3):e0152196. doi: 10.1371/journal.pone.0152196. eCollection 2016.

11.

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP.

Mol Ther. 2016 Jun;24(6):1135-49. doi: 10.1038/mt.2016.63. Epub 2016 Mar 29.

PMID:
27019998
12.

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.

Guo Y, Wang Y, Han W.

J Immunol Res. 2016;2016:3850839. doi: 10.1155/2016/3850839. Epub 2016 Feb 21. Review.

13.

T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.

Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA.

Oncoimmunology. 2015 Aug 12;5(1):e1040216. eCollection 2016.

14.

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.

Dai H, Wang Y, Lu X, Han W.

J Natl Cancer Inst. 2016 Jan 27;108(7). pii: djv439. doi: 10.1093/jnci/djv439. Print 2016 Jul. Review.

15.

Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents.

Daniotti JL, Lardone RD, Vilcaes AA.

Front Oncol. 2016 Jan 7;5:300. doi: 10.3389/fonc.2015.00300. eCollection 2015. Review.

16.

Enhancing adoptive T cell immunotherapy with microRNA therapeutics.

Ji Y, Hocker JD, Gattinoni L.

Semin Immunol. 2016 Feb;28(1):45-53. doi: 10.1016/j.smim.2015.11.006. Epub 2015 Dec 20. Review.

PMID:
26710685
17.

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.

Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Strömberg U, Savoldo B, Dotti G, Loskog A.

PLoS One. 2015 Dec 23;10(12):e0144787. doi: 10.1371/journal.pone.0144787. eCollection 2015.

18.

CAR-T cells are serial killers.

Davenport AJ, Jenkins MR, Ritchie DS, Prince HM, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ.

Oncoimmunology. 2015 Jun 1;4(12):e1053684. eCollection 2015 Dec.

19.

Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.

Tang XJ, Sun XY, Huang KM, Zhang L, Yang ZS, Zou DD, Wang B, Warnock GL, Dai LJ, Luo J.

Oncotarget. 2015 Dec 29;6(42):44179-90. doi: 10.18632/oncotarget.6175. Review.

20.

Immunotherapy and tumor microenvironment.

Tang H, Qiao J, Fu YX.

Cancer Lett. 2016 Jan 1;370(1):85-90. doi: 10.1016/j.canlet.2015.10.009. Epub 2015 Oct 19. Review.

PMID:
26477683
Items per page

Supplemental Content

Write to the Help Desk